Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Carboplatin and Vinorelbine in Platinum-Resistant Head and Neck Cancer
NCT01020864Phase 2Withdrawn
- Sponsor
- Pfeiffer Pharmaceuticals
- Start
- Jan 2010
- Primary completion
- Jan 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Pfeiffer Pharmaceuticals. Planned start Jan 2010; status: withdrawn.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01020864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01020864.